Drug Trial Radar · NCT00449956
MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
Last checked: Nov 20, 2026Latest source record: Jun 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
474
Actual
Start
Mar 12, 2007
Primary completion
Feb 16, 2008
Study completion Feb 16, 2008
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 21, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular hypertension.
Conditions
- Glaucoma
Interventions
dorzolamide hydrochloride (+) timolol maleateDrug
Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
Comparator: timolol maleateDrug
timolol maleate 0.5%, 8-week
Comparator: dorzolamide hydrochlorideDrug
dorzolamide hydrochloride 1%, 8-week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Intraocular Pressure (IOP) From Baseline at 8 WeeksTime frame: 8 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.